ExpreS2ion: Presentation of Q3 2026 report (Recording)

EXPRS2Analyst Comment12.11.2026, 16.08

Victor SkriverEquity Research Assistant

Today, ExpreS2ion Biotechnologies’ management presented the financial results for Q3 2026 and gave further insights into recent pipeline developments, with focus on the breast cancer candidate ES2B-C001 and the Phase I primary readout expected in Q1 2027. The session was followed by a Q&A.

Watch the recording here: https://www.inderes.dk/videos/expres2ion-biotech-presentation-of-q3-2026-interim-report

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. Victor Skriver, 16:07, 12/11-2026.

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.